Our research studies started in 2007 at the Central Laboratory of Ankara University Biotechnology Institute with financial support provided through the grants of TUBITAK (The Scientific and Technological Research Council of Turkey), Ankara University Research Fund, National Boron Institute, COST and IAEA.

Cancer, one of the most important global health threats, is a multifactorial and multigenic disease. Our team aims to identify novel diagnostic and prognostic biomarkers for cancer using data obtained from high-throughput genome and transcriptome-wide analyses. In this context, population genomics and stem cell biology are two other areas, on which our research group focuses.

In parallel with the missions of Biotechnology Institute, the identification of novel diagnostic and prognostic biomarkers requires the coordinated study of clinical and basic sciences. Starting from 2008 we have reconstructed our studies as a research program that brings different research groups together.